Arlington Office Patients: We apologize for any inconvenience. Currently our phones are down at our Arlington office. We hope for resolution soon. If you need to reach the Arlington office, please call our main number at 571.350.8400. Thank you for your patience. Note: If you’re a federal employee and have questions about continuing coverage, please speak to your Patient Benefits Specialist and visit our insurance page here: .
An orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic activity. Golvatinib binds to and inhibits the activities of both c-Met and VEGFR-2, which may inhibit tumor cell growth and survival of tumor cells that overexpress these receptor tyrosine kinases. c-Met and VEGFR-2 are upregulated in a variety of various tumor cell types and play important roles in tumor cell growth, migration and angiogenesis. Check for active clinical trials using this agent. (NCI Thesaurus)
Related Posts
Recent Posts
